Cargando…

Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome

BACKGROUND: Metabolic syndrome (MetS) is a clinical condition potentially promoting the development of atherosclerotic disease. To date, the clinical impact of elevated serum homocysteine (Hcy) levels in MetS is still under discussion. The aim of this cross sectional study was to evaluate the relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Piazzolla, Giuseppina, Candigliota, Mafalda, Fanelli, Margherita, Castrovilli, Anna, Berardi, Elsa, Antonica, Gianfranco, Battaglia, Stefano, Solfrizzi, Vincenzo, Sabbà, Carlo, Tortorella, Cosimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815401/
https://www.ncbi.nlm.nih.gov/pubmed/31673296
http://dx.doi.org/10.1186/s13098-019-0484-0
_version_ 1783463171435003904
author Piazzolla, Giuseppina
Candigliota, Mafalda
Fanelli, Margherita
Castrovilli, Anna
Berardi, Elsa
Antonica, Gianfranco
Battaglia, Stefano
Solfrizzi, Vincenzo
Sabbà, Carlo
Tortorella, Cosimo
author_facet Piazzolla, Giuseppina
Candigliota, Mafalda
Fanelli, Margherita
Castrovilli, Anna
Berardi, Elsa
Antonica, Gianfranco
Battaglia, Stefano
Solfrizzi, Vincenzo
Sabbà, Carlo
Tortorella, Cosimo
author_sort Piazzolla, Giuseppina
collection PubMed
description BACKGROUND: Metabolic syndrome (MetS) is a clinical condition potentially promoting the development of atherosclerotic disease. To date, the clinical impact of elevated serum homocysteine (Hcy) levels in MetS is still under discussion. The aim of this cross sectional study was to evaluate the relationship between MetS and hyperhomocysteinemia and the potential role of Hcy in the pathogenesis of atherosclerotic complications of MetS. METHODS: We recruited 300 outpatients with MetS. All patients underwent a medical history collection, physical examination, blood sampling and carotid ultrasound echo-color Doppler. According to Hcy levels, MetS patients were divided into two groups: “normal” (< 10.7 μmol/l; n = 140, group 1) and “high” Hcy (≥ 10.7 μmol/l; n = 160, group 2). Comparisons between groups were made by Student’s t-test or Chi-square test. The effects of potential covariates on group differences were evaluated by general linear models. The relationships between continuous variables were assessed by simple or multiple correlation and by linear regression. Multiple regression models were built to evaluate the effects of Hcy, together with other potential risk factors, on carotid atherosclerosis. RESULTS: Patients with high Hcy were predominantly male and slightly older than group 1 patients. Smokers and non-smokers exhibited similar Hcy levels, nor was a statistical relationship between pack-years and Hcy observed. Group 2 showed lower levels of folic acid, vitamin D, high density lipoprotein (HDL)-cholesterol and glomerular filtration rate (e-GFR) than group 1, but higher levels of C-peptide, uric acid and triglycerides. In all patients, Hcy was positively correlated with C-peptide and uric acid and negatively with folic acid and e-GFR. Intima-media thickness (IMT) and carotid stenosis degree were significantly higher in patients with high Hcy and a positive relationship between Hcy and both IMT and carotid stenosis was detected in all patients. Finally, Hcy atherogenic effects were independent of other well-known atherosclerosis risk factors. CONCLUSIONS: Our results highlight a link between MetS and hyperhomocysteinemia and a direct effect of Hcy on atherogenic process during MetS. Early correction of folic acid levels may contribute to prevent cardiovascular complications in MetS patients.
format Online
Article
Text
id pubmed-6815401
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68154012019-10-31 Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome Piazzolla, Giuseppina Candigliota, Mafalda Fanelli, Margherita Castrovilli, Anna Berardi, Elsa Antonica, Gianfranco Battaglia, Stefano Solfrizzi, Vincenzo Sabbà, Carlo Tortorella, Cosimo Diabetol Metab Syndr Research BACKGROUND: Metabolic syndrome (MetS) is a clinical condition potentially promoting the development of atherosclerotic disease. To date, the clinical impact of elevated serum homocysteine (Hcy) levels in MetS is still under discussion. The aim of this cross sectional study was to evaluate the relationship between MetS and hyperhomocysteinemia and the potential role of Hcy in the pathogenesis of atherosclerotic complications of MetS. METHODS: We recruited 300 outpatients with MetS. All patients underwent a medical history collection, physical examination, blood sampling and carotid ultrasound echo-color Doppler. According to Hcy levels, MetS patients were divided into two groups: “normal” (< 10.7 μmol/l; n = 140, group 1) and “high” Hcy (≥ 10.7 μmol/l; n = 160, group 2). Comparisons between groups were made by Student’s t-test or Chi-square test. The effects of potential covariates on group differences were evaluated by general linear models. The relationships between continuous variables were assessed by simple or multiple correlation and by linear regression. Multiple regression models were built to evaluate the effects of Hcy, together with other potential risk factors, on carotid atherosclerosis. RESULTS: Patients with high Hcy were predominantly male and slightly older than group 1 patients. Smokers and non-smokers exhibited similar Hcy levels, nor was a statistical relationship between pack-years and Hcy observed. Group 2 showed lower levels of folic acid, vitamin D, high density lipoprotein (HDL)-cholesterol and glomerular filtration rate (e-GFR) than group 1, but higher levels of C-peptide, uric acid and triglycerides. In all patients, Hcy was positively correlated with C-peptide and uric acid and negatively with folic acid and e-GFR. Intima-media thickness (IMT) and carotid stenosis degree were significantly higher in patients with high Hcy and a positive relationship between Hcy and both IMT and carotid stenosis was detected in all patients. Finally, Hcy atherogenic effects were independent of other well-known atherosclerosis risk factors. CONCLUSIONS: Our results highlight a link between MetS and hyperhomocysteinemia and a direct effect of Hcy on atherogenic process during MetS. Early correction of folic acid levels may contribute to prevent cardiovascular complications in MetS patients. BioMed Central 2019-10-26 /pmc/articles/PMC6815401/ /pubmed/31673296 http://dx.doi.org/10.1186/s13098-019-0484-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Piazzolla, Giuseppina
Candigliota, Mafalda
Fanelli, Margherita
Castrovilli, Anna
Berardi, Elsa
Antonica, Gianfranco
Battaglia, Stefano
Solfrizzi, Vincenzo
Sabbà, Carlo
Tortorella, Cosimo
Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
title Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
title_full Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
title_fullStr Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
title_full_unstemmed Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
title_short Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
title_sort hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815401/
https://www.ncbi.nlm.nih.gov/pubmed/31673296
http://dx.doi.org/10.1186/s13098-019-0484-0
work_keys_str_mv AT piazzollagiuseppina hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT candigliotamafalda hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT fanellimargherita hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT castrovillianna hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT berardielsa hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT antonicagianfranco hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT battagliastefano hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT solfrizzivincenzo hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT sabbacarlo hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome
AT tortorellacosimo hyperhomocysteinemiaisanindependentriskfactorofatherosclerosisinpatientswithmetabolicsyndrome